Avicanna Announces Repayment of Debentures
30 Agosto 2024 - 8:30AM
Avicanna Inc. (“
Avicanna” or the
“
Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN),
a commercial stage, international biopharmaceutical company focused
on the development advancement, and commercialization of
evidence-based, cannabinoid-based products, is pleased to announce
it has cleared and fully repaid $1,445,000 that was owed under the
Debentures of August 2 2023.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of cannabinoid-based products and formulations
for the global medical and pharmaceutical market segments. Avicanna
has an established scientific platform including R&D and
clinical development leading to the commercialization of more than
thirty proprietary, evidence-based finished products and supporting
four commercial stage business pillars.
-
Medical Cannabis formulary (RHO Phyto™): The
formulary offers a diverse range of proprietary products including
oral, sublingual, topical, and transdermal deliveries with varying
ratios of cannabinoids, supported by ongoing patient, and medical
community education. RHO Phyto is an established leading medical
brand in Canada currently available nationwide to patients across
several medical channels and continues to expand into new
international markets.
-
Medical cannabis care platform
(MyMedi.ca): MyMedi.ca is a medical cannabis care
platform formed with the aim to better serve medical cannabis
patients’ needs and enhance the patient journey. MyMedi.ca is
operated by Northern Green Canada Inc. and features a diverse
portfolio of products and bilingual pharmacist-led patient support
programs. MyMedi.ca also provides specialty services to distinct
patient groups such as veterans and collaborates with public and
private payers for adjudication and reimbursement. MyMedi.ca
provides educational resources to the medical community to
facilitate the incorporation of medical cannabis into health care
regimens.
-
Pharmaceutical products (Trunerox™) and
pipeline: Leveraging Avicanna’s scientific platform,
vertical integration, and real-world evidence, Avicanna has
developed a pipeline of proprietary, indication-specific
pharmaceutical products that are in various stages of clinical
development and commercialization. These cannabinoid-based drug
candidates aim to address unmet medical needs in the areas of
dermatology, chronic pain, and various neurological disorders.
Avicanna’s first indication-specific pharmaceutical drug,
Trunerox™, was approved Q1 2024 by the Health Authority of Colombia
INVIMA as an adjuvant treatment for seizures associated with
Lennox-Gastaut Syndrome and Dravet Syndrome.
-
Active pharmaceutical ingredients (Aureus Santa
Marta™): Active pharmaceutical ingredients (“API”)
supplied by the Company’s majority owned subsidiary Santa Marta
Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated
to providing various forms of high-quality CBD, THC and CBG to the
Company’s international partners for use in the development and
production of food, cosmetics, medical, and pharmaceutical
products. The business unit also forms part of the Company’s supply
chain and is a source of reliable input products for its consumer
retail, medical cannabis, and pharmaceutical products
globally.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit
www.avicanna.com, contact Ivana Maric by email at info@avicanna.com
or follow us on social media on LinkedIn, Twitter, Facebook or
Instagram.
If you are a Healthcare Professional and would
like to learn more about using medical cannabis in your practice,
please visit Avicenna Academy.
The Company posts updates through videos from
the official Company YouTube channel.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified using words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions. Although the Company believes that the expectations
and assumptions on which such forward looking information is based
are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company’s annual information form dated
April 1, 2024 filed with the Canadian securities regulators and
available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this news release are made as of the date of this
release. The Company disclaims any intent or obligation to update
any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
Avicanna (TSX:AVCN)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Avicanna (TSX:AVCN)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024